Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase ...

Amlitelimab reduced asthma exacerbations by over 70% in biomarker-defined patients at week 60. Sanofi plans a phase 3 amlitelimab trial; safety remained consistent over 60 weeks of treatment ...

Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma. Amlitelimab ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab advance into chronic rhinosinusitis, chronic obstructive pulmonary disease, and ...

New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma Itepekimab expanding into chronic ...

Sanofi SNY announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, for treating adults with moderate-to-severe asthma. The company also ...